Early experience with remdesivir in SARS-CoV-2 pneumonia

At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients h...

Descripción completa

Detalles Bibliográficos
Autores principales: Durante-Mangoni, Emanuele, Andini, Roberto, Bertolino, Lorenzo, Mele, Ferruccio, Florio, Letizia Lucia, Murino, Patrizia, Corcione, Antonio, Zampino, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229436/
https://www.ncbi.nlm.nih.gov/pubmed/32418190
http://dx.doi.org/10.1007/s15010-020-01448-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229436/
https://www.ncbi.nlm.nih.gov/pubmed/32418190
http://dx.doi.org/10.1007/s15010-020-01448-x

Ejemplares similares